Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 7.42 as of 2026-10-06T10:55:56.907Z.
Consensus retrieved: 2026-10-06T09:58:35.930Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T10:55:56.907Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ff8ae2f9cbeb57210f42079d57a4b4848323f7532bc30d4298c03d2fb3e77918
Forward PE Ratio (7.42) = Dated Quote Price ($2.04) / Consensus Forward EPS ($0.28)
FORWARD PE RATIO
7.42
SECTOR MEDIAN · HEALTHCARE
19.88
median of 117 covered companies
CURRENT VS SECTOR MEDIAN
-62.68%
vs the sector median at left
CareCloud, Inc.
Market Cap
$86.69M
Forward PE Ratio
7.42
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| CareCloud, Inc. (CCLD) | $86.69M | 7.42 |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | 8.74 |
| Biomea Fusion, Inc. (BMEA)vs › | $93.99M | N/A |
| Anixa Biosciences, Inc. (ANIX)vs › | $100.37M | N/A |
| Definitive Healthcare Corp. (DH)vs › | $104.07M | 5.06 |
Trailing P/E
29.2
reported TTM EPS
Forward P/E
7.4
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.28 implies +300.0% EPS growth vs the reported trailing $0.07.
At the dated quote price of $2.04, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.28 | $0.25 – $0.30 | 2 | 7.4x |
| 2027-12-31 | $0.30 | $0.27 – $0.34 | 2 | 6.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
